The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Intermittent dosing of zandelisib for patients with R/R FL: Results from the phase II TIDAL trial
|
The global, multicenter, open-label, single-arm, phase II TIDAL trial (NCT03768505) assessed the safety and efficacy of zandelisib, an oral PI3Kδ inhibitor, in 121 adult patients with R/R FL who had received ≥2 prior lines of therapy, including an anti-CD20 antibody and chemotherapy, and were PI3Kδ inhibitor-naïve.1 Patients were treated with zandelisib daily continuously for 8 weeks followed by intermittent dosing until disease progression or intolerability. The primary efficacy endpoint was ORR and the secondary endpoints included DoR, PFS, OS, and safety. Results from this trial were published in Hemasphere by Zelenetz, et al.1
|
| Key learnings |
| Response rates were high and durable, with an ORR of 73%, including a CR rate of 38% and a median DoR of 16.4 months. |
| With a median follow-up of 14.3 months, the median PFS was 11.6 months and the median OS was not reached. |
| Intermittent dosing of zandelisib was associated with a relatively low incidence of severe toxicities compared with continuous dosing, with dose interruptions and discontinuations due to AEs occurring in 49% and 17% of patients, respectively. |
| Grade 3–4 AEs of special interest for PI3Kδ inhibitors included diarrhea (6%), colitis (3%), pneumonia (4%), stomatitis (3%), cutaneous reactions (3%), ALT elevation (2%), non-infectious pneumonitis (1%), and PJP infections (1%). |
| Zandelisib treatment resulted in high rates of durable response in patients with R/R FL, and the intermittent dosing may offer improved tolerability over continuous PI3Kδ inhibition. |
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; CR, complete response; DoR, duration of response; FL, follicular lymphoma; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PI3K; phosphoinositide 3-kinase; PJP, Pneumocystis jirovecii pneumonia; R/R, relapsed/refractory.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
